News

June 19, marks World Sickle Cell Day, with the 2026 theme focusing on closing the survival gap and a push towards a universal cure. 20 years have passed since the…

AbstractSickle cell disease (SCD) is a systemic vasculopathy, which progressively remodels the heart and pulmonary circulation through chronic anemia, hemolysis,…

Fulcrum Therapeutics said it is discontinuing development of pociredir, its experimental oral treatment for sickle cell disease (SCD), after the U.S. Food and Drug…

 CorrectSequence Therapeutics Co., Ltd. (Correctseq), a clinical-stage biotechnology company pioneering transformer Base Editing (tBE) technology for severe…

With increasing population numbers worldwide, sickle cell disease (SCD) continues to pose a serious global health problem, especially in sub-Saharan Africa, where…

AbstractSickle cell disease (SCD) is an inherited hemoglobinopathy characterized by chronic hemolytic anemia, painful vaso-occlusive episodes, and end organ damage…

ABSTRACTOrbital involvement in sickle cell disease (SCD) is rare but potentially vision-threatening and often misdiagnosed due to overlap with infectious orbital…

A ten-year study has identified significant clinical outcomes for patients with sickle cell anemia treated with hydroxyurea, including reduced mortality rates,…

These are the benefits documented from 10 years of continuous hydroxyurea treatment provided in the NOHARM trial to a group of young children in Uganda, which has…

Sickle cell disease (SCD) is a group of inherited blood disorders that cause red blood cells to become hard, sticky, and crescent-shaped.Instead of flowing smoothly…